Sai Life Sciences Limited — Others, 13-08-2025: Monitoring Agency Report

Sai Life Sciences has received its IPO proceeds monitoring report for the quarter ended June 30, 2025. The company's monitoring agency confirmed no deviations in the utilization of funds from the objectives outlined in the IPO document. Out of the Rs 909.88 Cr net proceeds, Rs 720.00 Cr was fully used for debt repayment in previous quarters. During this quarter, Rs 16.57 Cr was deployed towards general corporate purposes, specifically for purchasing equipment and machinery. The remaining Rs 96.30 Cr from net proceeds, alongside some unspent issue expenses, totaling Rs 101.83 Cr, is currently held in fixed deposits and bank accounts. This provides a clear update on the company's use of public funds.